Sumitomo Mitsui Trust Group
AXSM icon

Sumitomo Mitsui Trust Group’s Axsome Therapeutics AXSM Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$392K Sell
1,600
-430
-21% -$93.3K ﹤0.01% 1006
2026
Q1 		$343K Buy
2,030
+130
+7% +$22.5K ﹤0.01% 982
2025
Q4 		$347K Buy
+1,900
New +$265K ﹤0.01% 998

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group's AXSM Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Axsome Therapeutics (AXSM) stake by 21% in Q2 2026, selling an estimated $93.3K and leaving 1,600 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #1006.

Sumitomo Mitsui Trust Group first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 1,600 shares of Axsome Therapeutics worth $392K as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 430 Axsome Therapeutics shares in Q2 2026, an estimated $93.3K.
  • Axsome Therapeutics made up ﹤0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #1006 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.